Thrivent Financial for Lutherans Boosts Holdings in Certara, Inc. (NASDAQ:CERT)

Thrivent Financial for Lutherans lifted its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 128.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 196,391 shares of the company's stock after acquiring an additional 110,481 shares during the quarter. Thrivent Financial for Lutherans owned 0.12% of Certara worth $2,091,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of CERT. Kopion Asset Management LLC grew its stake in Certara by 46.0% in the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock valued at $5,918,000 after purchasing an additional 175,005 shares during the period. Principal Financial Group Inc. grew its position in Certara by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock valued at $5,660,000 after buying an additional 15,739 shares during the period. Vontobel Holding Ltd. purchased a new stake in Certara during the fourth quarter worth about $1,295,000. Barclays PLC raised its position in Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company's stock worth $825,000 after acquiring an additional 46,880 shares during the period. Finally, Proficio Capital Partners LLC purchased a new position in Certara in the fourth quarter valued at about $148,000. 73.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CERT has been the subject of several research analyst reports. TD Cowen assumed coverage on shares of Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price target on the stock. William Blair restated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Barclays increased their price target on Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th. Finally, Stephens restated an "overweight" rating and issued a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $15.83.

Remove Ads

Certara Stock Performance

Shares of NASDAQ:CERT traded up $0.36 during midday trading on Wednesday, reaching $10.23. 1,888,582 shares of the company traded hands, compared to its average volume of 1,046,888. The firm's fifty day moving average price is $12.29 and its two-hundred day moving average price is $11.43. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -51.15, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.18.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.